Company / Free Cash Flow
KalVista Pharmaceuticals, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$153.3M
FY2025
5-year range
-$153.3M / -$76.5M
FY2021-FY2025
Trend
+0.0%
vs FY2024
Sector context
#132 of 194
Health Care
What the data says
At -$153M, KalVista Pharmaceuticals, Inc.'s free cash flow ranks #132 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 10 years, ranging from -$153M in FY2025 to $9M in FY2017.
Based on SEC 10-K filings.
-$153M in FY2025.
Declined from -$89M to -$153M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#132 of 194 in Health CareTop 68% of 194This company -$153.3M Sector average $470.8M
▼
-132.6% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 0.0% year-over-year.
- Ranks #132 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$153.3M | +0.0% |
| FY2024 | -$153.3M | -71.8% |
| FY2023 | -$89.3M | -16.8% |
| FY2022 | -$76.5M | +3.3% |
| FY2021 | -$79.1M | -161.3% |
| FY2020 | -$30.3M | -27.1% |
| FY2019 | -$23.8M | -80.7% |
| FY2018 | -$13.2M | -244.2% |
| FY2017 | $9.1M | +138.4% |
| FY2016 | -$23.8M | -79.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026